Opaleye Management’s Eton Pharmaceutcials ETON Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $104M | Hold |
2,860,000
| – | – | 9.38% | 2 |
|
|
2026
Q1 | $70.6M | Hold |
2,860,000
| – | – | 9.3% | 3 |
|
|
2025
Q4 | $48.4M | Hold |
2,860,000
| – | – | 6.38% | 3 |
|
|
2025
Q3 | $62.1M | Hold |
2,860,000
| – | – | 8.79% | 2 |
|
|
2025
Q2 | $40.8M | Buy |
2,860,000
+7,930
| +0.3% | +$125K | 8.25% | 2 |
|
|
2025
Q1 | $37M | Hold |
2,852,070
| – | – | 8.24% | 2 |
|
|
2024
Q4 | $38M | Buy |
2,852,070
+72,070
| +3% | +$731K | 6.65% | 4 |
|
|
2024
Q3 | $16.7M | Buy |
2,780,000
+385,000
| +16% | +$1.63M | 2.78% | 10 |
|
|
2024
Q2 | $7.88M | Sell |
2,395,000
-50,781
| -2% | -$178K | 1.8% | 16 |
|
|
2024
Q1 | $9.17M | Sell |
2,445,781
-84,106
| -3% | -$367K | 2% | 17 |
|
|
2023
Q4 | $11.1M | Buy |
2,529,887
+99,617
| +4% | +$399K | 2.95% | 9 |
|
|
2023
Q3 | $10.1M | Buy |
2,430,270
+145,270
| +6% | +$561K | 3.3% | 10 |
|
|
2023
Q2 | $7.97M | Buy |
2,285,000
+100,000
| +5% | +$368K | 1.91% | 12 |
|
|
2023
Q1 | $8.41M | Buy |
2,185,000
+15,000
| +0.7% | +$54.7K | 2.52% | 9 |
|
|
2022
Q4 | $6.12M | Sell |
2,170,000
-351,000
| -14% | -$944K | 2.13% | 15 |
|
|
2022
Q3 | $5.29M | Buy |
2,521,000
+58,500
| +2% | +$146K | 2.19% | 15 |
|
|
2022
Q2 | $6.45M | Buy |
2,462,500
+83,225
| +3% | +$279K | 2.91% | 13 |
|
|
2022
Q1 | $10.4M | Sell |
2,379,275
-5,725
| -0.2% | -$22.5K | 3.22% | 11 |
|
|
2021
Q4 | $10.2M | Sell |
2,385,000
-703,100
| -23% | -$3.36M | 2.17% | 15 |
|
|
2021
Q3 | $15.6M | Sell |
3,088,100
-604,500
| -16% | -$3.14M | 2.91% | 10 |
|
|
2021
Q2 | $29.3M | Sell |
3,692,600
-347,400
| -9% | -$2.57M | 4.87% | 6 |
|
|
2021
Q1 | $29.6M | Hold |
4,040,000
| – | – | 4.34% | 6 |
|
|
2020
Q4 | $32.8M | Buy |
4,040,000
+400,000
| +11% | +$3.09M | 4.29% | 4 |
|
|
2020
Q3 | $28.8M | Hold |
3,640,000
| – | – | 5.62% | 3 |
|
|
2020
Q2 | $19.8M | Hold |
3,640,000
| – | – | 4.01% | 5 |
|
|
2020
Q1 | $14.9M | Buy |
3,640,000
+2,170,544
| +148% | +$12.7M | 3.95% | 8 |
|
|
2019
Q4 | $10.6M | Buy |
1,469,456
+304,456
| +26% | +$1.88M | 2.08% | 20 |
|
|
2019
Q3 | $7.36M | Buy |
1,165,000
+90,000
| +8% | +$574K | 2.66% | 18 |
|
|
2019
Q2 | $8.49M | Buy |
1,075,000
+310,227
| +41% | +$2.41M | 2.59% | 17 |
|
|
2019
Q1 | $6.12M | Buy |
764,773
+241,773
| +46% | +$1.68M | 1.69% | 25 |
|
|
2018
Q4 | $3.2M | Buy |
+523,000
| New | +$3.21M | 1.19% | 26 |
|
Other funds holding ETON
Opaleye Management's ETON Position: Q2 2026 in Review
Opaleye Management held its Eton Pharmaceutcials (ETON) position steady in Q2 2026 at 2,860,000 shares worth $104M. The position accounts for 9.38% of the portfolio, ranked #2.
Opaleye Management first reported a position in ETON in Q4 2018 and has held it in 31 quarters since. 164 funds tracked by Wall St. Rank hold ETON as of Q2 2026.
- Opaleye Management held 2,860,000 shares of Eton Pharmaceutcials worth $104M as of Q2 2026.
- Opaleye Management left its Eton Pharmaceutcials share count unchanged in Q2 2026.
- Eton Pharmaceutcials made up 9.38% of Opaleye Management's portfolio in Q2 2026, its #2 holding.
- Opaleye Management first reported a position in Eton Pharmaceutcials in Q4 2018 and has held it in 31 quarters since.
- 164 funds tracked by Wall St. Rank held Eton Pharmaceutcials as of Q2 2026.
Based on Opaleye Management's 13F filing for Q2 2026, filed 14 Aug 2026.